Presented at SABCS 2024 by Dr. Vicente Valero, the NRG-BR004 trial evaluated adding atezolizumab to first-line THP therapy in HER2+ metastatic breast cancer (MBC).
Key Findings:
PFS: 38.1 months (atezolizumab) vs. 22.2 months (placebo) (HR=0.73, p=0.12).
OS: Immature data, showing a trend toward benefit (HR=0.8).
Safety: Comparable adverse events, but six deaths in the atezolizumab arm led to early discontinuation.
Takeaway: Atezolizumab did not improve outcomes significantly in HER2+ MBC, but checkpoint inhibitors remain promising in select patients. More studies are needed!
Thanks to Dr. Vicente Valero and all the investigators, patients, and research teams for their contributions.
